prikaz prve stranice dokumenta Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
  Preuzmi
PDF 2.84 MB
Znanstveni rad - Izvorni znanstveni rad
Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
Modern Pathology, 35 (2022), 12; 1888-1899. https://doi.org/10.1038/s41379-022-01145-0
(ETOP Mesoscape consortium) Rüschoff, Jan Hendrik; Haberecker, Martina; Tsourti, Zoi; Nackaerts, Kristiaan; de Perrot, Marc; Brcic, Luka; Nadal, Ernest; Tsimpoukis, Sotirios; Gray, Steven G.; Ampollini, Luca; Aerts, Joachim G.; Felley-Bosco, Emanuela; Kirschner, Michaela B.; Monkhorst, Kim; Weynand, Birgit; Bavaghar-Zaeimi, Fatemeh; Samaržija, Miroslav; Llatjos, Roger; Finn, Stephen P.; Silini, Enrico; von der Thüsen, Jan; Marti, Nesa; Vervita, Karerina; Kammler, Roswitha; Peters, Solange; Stahel, Rolf A.; Baas, Paul; Opitz, Isabelle; Stahel, Rolf; Hiltbrunner, Anita; Kammler, Rosita; Marti, Nesa; Vagenknecht, Patrick; Ruepp, Barbara; Dafni, Urania; Tsourti, Zoi; Zygoura, Panagiota; Vervita, Katerina; Dimopoulou, Georgia; Andriakopoulou, Charitini; Stavrou, Androniki; Rüschoff, Jan H.; Haberecker, Martina; Dettwiler, Susanne; Prutek, Fabiola; Mittmann, Christiane; Opitz, Isabelle Više autora...

Citirajte ovaj rad

Rüschoff, J. H., Haberecker, M., Tsourti, Z., Nackaerts, K., de Perrot, M., Brcic, L. ... Opitz, I. (2022). Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project. Modern Pathology, 35. (12), 1888-1899. doi: 10.1038/s41379-022-01145-0

Rüschoff, Jan Hendrik, et al. "Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project." Modern Pathology, vol. 35, br. 12, 2022, str. 1888-1899. https://doi.org/10.1038/s41379-022-01145-0

Rüschoff, Jan Hendrik, Martina Haberecker, Zoi Tsourti, Kristiaan Nackaerts, Marc de Perrot, Luka Brcic, Ernest Nadal, et al. "Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project." Modern Pathology 35, br. 12 (2022): 1888-1899. https://doi.org/10.1038/s41379-022-01145-0

Rüschoff, J. H., et al. (2022) 'Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project', Modern Pathology, 35(12), str. 1888-1899. doi: 10.1038/s41379-022-01145-0

Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L, i sur.. Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project. Modern Pathology [Internet]. 12.2022. [pristupljeno 29.09.2024.];35(12):1888-1899. doi: 10.1038/s41379-022-01145-0

J. H. Rüschoff, et al., "Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project", Modern Pathology, vol. 35, br. 12, str. 1888-1899, Prosinac 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:000556. [Citirano: 29.09.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:000556
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
AutorJan Hendrik Rüschoff
AutorMartina Haberecker
AutorZoi Tsourti
AutorKristiaan Nackaerts
AutorMarc de Perrot
AutorLuka Brcic
AutorErnest Nadal
AutorSotirios Tsimpoukis
AutorSteven G. Gray
AutorLuca Ampollini
AutorJoachim G. Aerts
AutorEmanuela Felley-Bosco
AutorMichaela B. Kirschner
AutorKim Monkhorst
AutorBirgit Weynand
AutorFatemeh Bavaghar-Zaeimi
AutorMiroslav Samaržija
AutorRoger Llatjos
AutorStephen P. Finn
AutorEnrico Silini
AutorJan von der Thüsen
AutorNesa Marti
AutorKarerina Vervita
AutorRoswitha Kammler
AutorSolange Peters
AutorRolf A. Stahel
AutorPaul Baas
AutorIsabelle Opitz
AutorRolf Stahel
AutorAnita Hiltbrunner
AutorRosita Kammler
AutorNesa Marti
AutorPatrick Vagenknecht
AutorBarbara Ruepp
AutorUrania Dafni
AutorZoi Tsourti
AutorPanagiota Zygoura
AutorKaterina Vervita
AutorGeorgia Dimopoulou
AutorCharitini Andriakopoulou
AutorAndroniki Stavrou
AutorJan H. Rüschoff
AutorMartina Haberecker
AutorSusanne Dettwiler
AutorFabiola Prutek
AutorChristiane Mittmann
AutorIsabelle Opitz
KolaboracijaETOP Mesoscape consortium
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Pleural mesothelioma (PM) is an aggressive malignancy with poor prognosis. Although histology and pathologic stage are important prognostic factors, better prognostic biomarkers are needed. The ribosomal protein S6 is a downstream target of the phosphatidylinositol 3-kinase (PI3K) pathway involved in protein synthesis and cell proliferation. In previous studies, low phosphorylated S6 (pS6) immunoreactivity was significantly correlated with longer progression-free survival (PFS) and overall survival (OS) in PM patients. We aimed to correlate pS6 expression to clinical data in a large multi-centre PM cohort as part of the European Thoracic Oncology Platform (ETOP) Mesoscape project. Tissue Micro Arrays (TMAs) of PM were constructed and expression of pS6 was evaluated by a semi-quantitatively aggregate H-score. Expression results were correlated to patient characteristics as well as OS/PFS. pS6 IHC results of 364 patients from 9 centres, diagnosed between 1999 and 2017 were available. The primary histology of included tumours was epithelioid (70.3%), followed by biphasic (24.2%) and sarcomatoid (5.5%). TMAs included both treatment-naïve and tumour tissue taken after induction chemotherapy. High pS6 expression (181 patients with H-score>1.41) was significantly associated with less complete resection. In the overall cohort, OS/PFS were not significantly different between pS6-low and pS6-high patients. In a subgroup analysis non-epithelioid (biphasic and sarcomatoid) patients with high pS6 expression showed a significantly shorter OS (p < 0.001, 10.7 versus 16.9 months) and PFS (p < 0.001, 6.2 versus 10.8 months). In subgroup analysis, in non-epithelioid PM patients high pS6 expression was associated with significantly shorter OS and PFS. These exploratory findings suggest a clinically relevant PI3K pathway activation in non-epithelioid PM which might lay the foundation for future targeted treatment strategies.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaModern Pathology
Brojčani podacivol. 35, br. 12, str. 1888-1899
p-ISSN0893-3952
DOIhttps://doi.org/10.1038/s41379-022-01145-0
URN:NBNurn:nbn:hr:105:000556
Datum objave publikacije2022-12
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S0893395222055016
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-02-14 08:10:35